Objectives: The objective was to describe patterns of rapid influenza test ordering, diagnosis of influenza, and antiviral prescribing by the treating physician for children and adults presenting to emergency departments (EDs) with fever and acute respiratory symptoms in Winston-Salem, North Carolina, over two influenza seasons.

Methods: The authors prospectively enrolled patients presenting to the ED with fever and acute respiratory symptoms for two influenza seasons: H1N1 pandemic of September 2009 through mid-May 2010 and November 2010 through April 2011. Enrolled patients had nose or and throat swabs obtained and tested for influenza by viral culture and polymerase chain reaction (PCR) testing. Demographic information and medical history were obtained by patient or guardian report. Testing, treatment, and discharge diagnosis from the ED visit, as well as medical history and insurance status, were ascertained from chart review.

Results: Among 2,293 eligible patients approached, 1,657 (72%) were enrolled, of whom 38% were younger than 18 years, 47% were 18 to 49 years, and 15% were 50 years of age and older. Overall, 14% had culture- or PCR-confirmed influenza. The odds of 1) rapid influenza test ordering, 2) a physician diagnosis of influenza, and 3) prescribing antiviral treatment during the ED visit were fourfold higher among patients with than without culture- or PCR-confirmed influenza. The odds of rapid influenza test ordering were threefold lower in 2009/2010 than 2010/2011, whereas the odds of physician diagnosis of influenza and antiviral prescriptions were 2- and 3.5-fold higher, respectively.

Conclusions: In 2009/2010 compared to 2010/2011, the odds of rapid influenza test ordering were lower, whereas the odds of influenza-specific discharge diagnoses and antiviral prescriptions were higher among patients presenting to the ED with culture/PCR-confirmed influenza. These results demonstrated a gap between clinical practice and recommendations for the diagnosis and treatment of influenza from the Centers for Disease Control and Prevention (CDC).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775287PMC
http://dx.doi.org/10.1111/acem.12175DOI Listing

Publication Analysis

Top Keywords

rapid influenza
16
influenza test
16
test ordering
16
influenza
15
diagnosis influenza
12
odds rapid
12
diagnosis treatment
8
influenza antiviral
8
fever acute
8
acute respiratory
8

Similar Publications

Background: Rapid identification of individuals with acute respiratory infections is crucial for preventing nosocomial infections. For rapid diagnosis, especially in EDs, lateral flow devices (LFDs) are a convenient, inexpensive option with a rapid turnaround. Several 'multiplex' LFDs (M-LFDs) now exist, testing for multiple pathogens from a single swab sample.

View Article and Find Full Text PDF

Building a Fast Response Capability for Emerging Infectious Diseases Within the Biomedical Advanced Research and Development Authority.

Health Secur

January 2025

Robert A. Johnson, PhD, is Director, Medical Countermeasures Programs, and Gary L. Disbrow, PhD, is Director, Center for Biomedical Advanced Research and Development Authority (BARDA), Washington, DC. Terence M. Barnhart, PhD, is Senior Strategy Implementation Leader, Tunnell Government Services, Inc. (Contractor Supporting BARDA), Washington, DC.

From influenza to COVID-19, emerging infectious diseases have taken a heavy toll on lives and resources. Emerging infectious diseases represent one of the largest threats to national security. The primary mission of the Center for Biomedical Advanced Research and Development Authority (BARDA), within the US Administration for Strategic Preparedness and Response, is to support the advanced development of medical countermeasures (MCMs) for public health security threats, including select infectious diseases.

View Article and Find Full Text PDF

To evaluate the performance of three rapid influenza diagnostic tests (RIDTs) for detecting influenza A and B viruses compared to RT-PCR. A total of 291 subjects with acute respiratory infections were enrolled. Respiratory specimens were collected and tested for influenza A and B viruses using three RIDTs.

View Article and Find Full Text PDF

Lateral flow assay with automatic signal amplification based on delayed substrate release.

Talanta

January 2025

State Key Laboratory of Food Science and Resources, Jiangnan University, Lihu Road 1800, Wuxi, 214122, PR China; School of Food Science and Technology, Jiangnan University, Lihu Road 1800, Wuxi, 214122, PR China; International Joint Laboratory on Food Safety, Jiangnan University, Lihu Road 1800, Wuxi, 214122, PR China.

The low sensitivity of Lateral flow assay (LFA) limits its application in rapid detection for trace targets. LFAs with nanozyme (nanozyme-LFA) as signal labels have demonstrated excellent performance in point of care testing (POCT). However, additional operational steps for substrate catalysis in nanozyme LFA are required, which makes the nanozyme-LFA operation complicated.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!